Ionis Pharmaceuticals, Inc announced that its Phase III cardiovascular outcome clinical trial "Cardio-Ttransform" for the drug Eplontersen failed to meet its primary endpoint in the analysis at week 140.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The Nasdaq 100 rebalancing will take effect before the U.S. stock market opens on Monday, SpaceX (SPCX.US) weight significantly rises to 2.82%.
The Nasdaq 100 Index quarterly rebalancing will take effect before the US stock market opens on September 21 (Monday). The main change is that SpaceX (SPCX.US) will see its index weighting significantly increase from about 1.28% to 2.82%.
WTI falls to near $93.50 as Middle East diplomacy hopes ease supply fears
South Korea's exports in the first 20 days of September continued strong momentum, with chip exports soaring by 259%, remaining a key driver of growth.
Early September exports from South Korea help maintain strong momentum in the chip boom.
Crypto prices
More
